Prescription Drug Affordability Board - Upper Payment Limits
Impact
If enacted, HB 279 would amend existing health laws in Maryland, specifically enhancing the regulatory capabilities of the Prescription Drug Affordability Board to manage the cost of prescription medications. This shift could significantly influence the operational landscape for pharmaceutical companies and state-funded healthcare programs, establishing a framework for price management that could lead to reduced costs for citizens reliant on state health services. The legislation emphasizes not only setting limits on drug prices but also ensuring that these limits do not hinder the availability of necessary medications, particularly during shortages.
Summary
House Bill 279 involves the establishment of upper payment limits for prescription drug products, aiming to tackle affordability challenges faced by consumers. The bill mandates the Prescription Drug Affordability Board to develop a process to set these limits based on defined criteria, which includes the costs of administering and delivering the drugs. The intent behind the legislation is to provide a systematic approach to enhance access to necessary medications by preventing excessive pricing that contributes to affordability issues in the state. It also reestablishes the Board's authority to oversee these limits and outlines an appeals process for those dissatisfied with the decisions made regarding payment limits.
Sentiment
The sentiment surrounding HB 279 appears to be largely supportive, particularly among advocates for consumer health and affordability in prescription medications. While proponents emphasize the necessity of controlling drug prices to promote public welfare, there are concerns regarding potential pushbacks from pharmaceutical manufacturers who may argue that price controls could stifle innovation or limit the availability of certain drugs. Overall, the bill has garnered favor from those urging for reform in how prescription drug prices are managed, reflecting a broader trend toward public health advocacy within state legislatures.
Contention
Notable points of contention surrounding the bill include the balance of state control over drug pricing versus the potential impact it may have on pharmaceutical companies' pricing strategies and the availability of medications. Critics may voice concerns that stringent upper payment limits could influence the willingness of drug manufacturers to supply certain products or invest in new drug development. The inclusion of provisions that ensure drug availability even when limits are imposed is a critical aspect of the dialogue, as stakeholders strive to maintain both affordable pricing and an adequate supply of necessary medications in the state.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Maryland Medical Assistance Program and Health Insurance - Coverage and Utilization Review - Drugs Reviewed by the Prescription Drug Affordability Board
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.